ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,529 | -0.2% | 217,270 | +14.6% | 0.00% | 0.0% |
| Q2 2023 | $4,540 | +45.6% | 189,540 | +14.4% | 0.00% | +200.0% |
| Q1 2023 | $3,118 | -45.9% | 165,678 | -54.2% | 0.00% | -50.0% |
| Q4 2022 | $5,760 | -99.9% | 361,809 | +10.6% | 0.00% | -66.7% |
| Q3 2022 | $5,349,000 | +260.7% | 327,047 | +210.7% | 0.01% | +500.0% |
| Q2 2022 | $1,483,000 | -19.4% | 105,266 | +38.5% | 0.00% | 0.0% |
| Q1 2022 | $1,839,000 | -76.1% | 75,986 | -77.0% | 0.00% | 0.0% |
| Q4 2021 | $7,694,000 | +350.2% | 329,676 | +220.2% | 0.00% | 0.0% |
| Q3 2021 | $1,709,000 | -15.5% | 102,952 | +24.2% | 0.00% | 0.0% |
| Q2 2021 | $2,022,000 | +14.0% | 82,903 | +20.5% | 0.00% | 0.0% |
| Q1 2021 | $1,774,000 | -24.4% | 68,779 | +56.7% | 0.00% | 0.0% |
| Q4 2020 | $2,347,000 | -4.2% | 43,884 | -26.1% | 0.00% | 0.0% |
| Q3 2020 | $2,450,000 | -69.7% | 59,401 | -64.4% | 0.00% | -83.3% |
| Q2 2020 | $8,082,000 | -13.8% | 166,763 | -24.9% | 0.01% | -25.0% |
| Q1 2020 | $9,379,000 | -69.0% | 221,991 | -68.6% | 0.01% | -52.9% |
| Q4 2019 | $30,213,000 | +18.9% | 706,245 | +0.0% | 0.02% | +6.2% |
| Q3 2019 | $25,413,000 | +38.3% | 706,078 | +2.7% | 0.02% | +33.3% |
| Q2 2019 | $18,380,000 | +107.8% | 687,594 | +108.7% | 0.01% | +100.0% |
| Q1 2019 | $8,844,000 | -19.4% | 329,452 | -51.4% | 0.01% | -33.3% |
| Q4 2018 | $10,967,000 | -56.2% | 678,284 | -43.7% | 0.01% | -47.1% |
| Q3 2018 | $25,013,000 | +401.6% | 1,204,863 | +268.9% | 0.02% | +325.0% |
| Q2 2018 | $4,987,000 | -19.0% | 326,638 | +19.2% | 0.00% | -20.0% |
| Q1 2018 | $6,155,000 | -30.5% | 274,011 | -6.9% | 0.01% | -28.6% |
| Q4 2017 | $8,860,000 | -48.6% | 294,251 | -35.7% | 0.01% | -61.1% |
| Q3 2017 | $17,230,000 | +36.3% | 457,411 | +1.0% | 0.02% | +38.5% |
| Q2 2017 | $12,637,000 | +48.4% | 453,104 | +83.0% | 0.01% | +44.4% |
| Q1 2017 | $8,514,000 | -69.6% | 247,590 | -74.5% | 0.01% | -70.0% |
| Q4 2016 | $28,036,000 | +351.9% | 972,146 | +398.5% | 0.03% | +328.6% |
| Q3 2016 | $6,204,000 | -21.3% | 195,016 | -19.7% | 0.01% | -30.0% |
| Q2 2016 | $7,888,000 | -73.7% | 242,988 | -78.2% | 0.01% | -78.3% |
| Q1 2016 | $30,038,000 | +370.4% | 1,112,572 | +509.8% | 0.05% | +475.0% |
| Q4 2015 | $6,386,000 | +51.3% | 182,442 | +42.7% | 0.01% | +60.0% |
| Q3 2015 | $4,220,000 | -23.1% | 127,854 | -4.5% | 0.01% | -16.7% |
| Q2 2015 | $5,491,000 | -1.3% | 133,946 | -22.9% | 0.01% | 0.0% |
| Q1 2015 | $5,562,000 | -49.1% | 173,817 | -50.7% | 0.01% | -45.5% |
| Q4 2014 | $10,923,000 | +54.9% | 352,354 | +19.9% | 0.01% | +83.3% |
| Q3 2014 | $7,053,000 | +44.9% | 293,846 | +32.9% | 0.01% | 0.0% |
| Q2 2014 | $4,866,000 | -1.2% | 221,124 | +7.7% | 0.01% | +20.0% |
| Q1 2014 | $4,925,000 | -54.9% | 205,224 | -54.9% | 0.01% | -58.3% |
| Q4 2013 | $10,913,000 | +2.8% | 454,644 | +15.6% | 0.01% | -7.7% |
| Q3 2013 | $10,616,000 | +118.6% | 393,133 | +46.9% | 0.01% | +116.7% |
| Q2 2013 | $4,857,000 | – | 267,637 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |